Search Legislation

The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006

 Help about what version

What Version

  • Latest available (Revised)
  • Original (As made)
 Help about opening options

Opening OptionsExpand opening options

Status:

This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

Amendment of regulation 2 of the principal Regulations

This section has no associated Explanatory Memorandum

2.  In regulation 2 of the principal Regulations (interpretation), in paragraph (1)—

(a)in the definition of “chief investigator”, in sub-paragraph (b), omit “care”;

(b)for the definition of “EEA State” substitute the following definition—

“EEA State” means a Member State, Norway, Iceland or Liechtenstein;;

(c)omit the definition of “EEA Agreement”; and

(d)after the definition of “export”, insert the following definition—

“the GCP Directive” means Commission Directive 2005/28/EC laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products(1);.

(1)

OJ No. L91, 9.4.2005, p.13.

Back to top

Options/Help